EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A pH-Sensitive cRGD-PEG-siRNA Conjugated Compound Targeting Glioblastoma

Qing Su, Junxiao Chen, Ziyuan Liu, Yiqi Fan, Shuai He iD

Bioconjugate Chemistry · 2024

DOI: 10.1021/acs.bioconjchem.4c00255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2024. Verfasst von Qing Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510655, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Glioblastoma, Polyethylene Glycols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma ranks among the most prevalent primary intracranial tumors, characterized by high mortality and poor prognosis. Chemotherapy remains a key treatment strategy for gliomas, though most current drugs suffer from limited efficacy and significant toxicity. This study focuses on a cRGD-siEGFR coupling compound synthesized in a previous stage. Prior research indicated that cRGD-siEGFR molecules exhibited certain targeting and antitumor properties but faced issues of inadequate targeting, low efficacy, and high renal toxicity. To enhance antitumor efficacy and mitigate side effects, a pH-responsive, long-circulating, and highly targeted siRNA delivery system, the cRGD-PEG-siEGFR conjugate, was developed. The targeting, antitumor effects, and biological distribution of cRGD-PEG-siEGFR were examined. The results demonstrated that cRGD-PEG-siEGFR was effectively taken up by αvβ3-positive U87MG cells, specifically silenced EGFR gene expression, and exhibited antitumor effects. In normal physiological conditions, it avoided uptake by normal cells, thereby reducing side effects. Furthermore, in vivo biodistribution experiments revealed that cRGD-PEG-siEGFR, compared to cRGD-siEGFR, significantly decreased renal accumulation and exhibited prolonged circulation. Consequently, cRGD-PEG-siRNA emerges as a promising drug candidate with attributes of long circulation, high targeting, pH responsiveness, and substantial antitumor efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingGlioblastomaPolyethylene GlycolsHumansHydrogen-Ion ConcentrationAnimalsCell Line, TumorMicePeptides, CyclicTissue DistributionAntineoplastic AgentsErbB ReceptorsMice, NudeBrain Neoplasms

Substanzen

RNA, Small InterferingPolyethylene Glycolscyclic arginine-glycine-aspartic acid peptidePeptides, CyclicAntineoplastic AgentsErbB Receptors

Autor:innen und Institutionen

  • Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510655, China.

ORCID-Profile: Shuai He

Förderung

  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Su, Q., Chen, J., Liu, Z., Fan, Y., & He, S. (2024). A pH-Sensitive cRGD-PEG-siRNA Conjugated Compound Targeting Glioblastoma. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.4c00255

Vancouver

Su Q, Chen J, Liu Z, Fan Y, He S. A pH-Sensitive cRGD-PEG-siRNA Conjugated Compound Targeting Glioblastoma. Bioconjugate Chemistry. 2024. doi:10.1021/acs.bioconjchem.4c00255

BibTeX
@article{Su2024,
  author = {Su, Qing and Chen, Junxiao and Liu, Ziyuan and Fan, Yiqi and He, Shuai},
  title = {A pH-Sensitive cRGD-PEG-siRNA Conjugated Compound Targeting Glioblastoma},
  journal = {Bioconjugate Chemistry},
  year = {2024},
  doi = {10.1021/acs.bioconjchem.4c00255}
}
Kostenlos starten →